You are viewing the site in preview mode

Skip to main content

Table 1 Clinical characteristics and treatment outcome details of pulmonary, drug-resistant TB patients in Chhattisgarh-Andhra Pradesh border, India

From: Treating drug-resistant tuberculosis in a low-intensity chronic conflict setting in India

Case Age Sex State of origin AFB smear result Resistance profile DST TB Resistance pattern Treatment regimen Duration (months) Adverse events Outcome
1 50 M AP Pos S,H,Z PDR Inj Km/Mx/ R/E 14 Oto-toxicity Cured
2 40 F AP Neg H Mono-R Inj Km/Mx/ R/E/Z 14 - Cured
3 25 M AP Neg H,Z PDR - - - LTFU
4 45 M AP Pos S,H,R,Z,E MDR Inj Cm/Mx/ Eto/Cs/PAS 24 GI dista Cured
5 40 M CG Pos H Mono-R Inj Cm/Mx/ R/E/Z 12 Psychb Cured
6 45 M CG Pos S,H,R,Z MDR Inj Cm/Mx/ Eto/Cs/PAS 24 - Cured
7 45 M CG Pos S,H,Eto PDR Inj Cm/Mx/ R/E/Z 13 Renal dysc Cured
8 45 M CG Pos S,H PDR Inj Cm/Mx/ R/E/Z 13 - Cured
9 45 F CG Pos H,R MDR Inj Km/Lx/ Eto/Cs/E/Z 7 - On-treatment┼
10 13 F CG Pos H Mono-R H/R/Z/E 6 - On-treatment┼
11 35 M AP Neg H,R,Z MDR Inj Km/Lx/ Eto/Cs/E/Z 7 - On-treatment┼
12 25 M CG Pos H,R MDR - - - Died
13 60 M AP Pos H Mono-R - - - Refused treatment
  1. M: Male, F: Female, AP: Andhra-Pradesh, CG: Chhattisgarh, Pos: Positive, Neg: Negative.
  2. aGI dist: Gastro-intestinal disturbance, bPsych: Psychological complaints, cRenal dys : Renal dysfunction.
  3. Mono-R: Mono-resistance tuberculosis; defined as drug-resistant TB case whose recovered M. tuberculosis isolate is resistant to one first line anti-TB drug.
  4. PDR: Poly-resistance tuberculosis; defined as drug-resistant TB case whose recovered M. tuberculosis isolate is resistant to more than one first line anti-TB drug, but not MDR-TB.
  5. MDR: Multi-drug resistant tuberculosis; defined as drug-resistant TB case whose recovered M. tuberculosis isolate is resistant in-vitro to isoniazid and rifampicin with or without resistance to other anti-tubercular drugs based on DST results.
  6. S: Streptomycin, H: Isoniazid, R: Rifampicin, Z: Pyrazinamide, E: Ethambutol, Eto: Ethionamide, Km: Kanamycin, Mx: Moxifloxacin, Cm: Capreomycin, Cs: Cycloserine, PAS: Para-amino salicylic acid, Lx: Levofloxacin.
  7. LTFU: Lost to follow up.
  8. ┼Culture negative at end of intensive phase; currently in continuation phase.
Back to article page

Conflict and Health

ISSN: 1752-1505